Urinary c-peptide/creatinine ratio can distinguish maturity-onset diabetes of the young from type 1 diabetes in children and adolescents: A single-center experience

Hormone Research in Paediatrics

Volumn 84, Issue 1, 2015, Pages 54-61

  Agladioglu, Sebahat Ylmaz ^a   Sagsak, Elif ^a   Aycan, Zehra ^a  

^a Dr Sami Ulus Children's Health Diseases Training and Research Hospital   (Turkey)

Author keywords

Diabetes mellitus; Maturity onset diabetes of the young; Urinary C peptide

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; CREATININE;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; BODY MASS; C PEPTIDE CREATININE RATIO; CHILDHOOD DISEASE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC DIET; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEAL; NEXT GENERATION SEQUENCING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; URINALYSIS; CHILD; URINE;

ADOLESCENT; C-PEPTIDE; CHILD; CREATININE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE;

EID: 84939570872     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000375410     Document Type: Article

References (24)

1. Ledermann HM: Is maturity onset diabetes at young age (MODY) more common in Europe than previously assumed? Lancet 1995; 345: 648.
2. Craig ME, Hattersley A, Donaghue KC: Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes 2009; 10(suppl 12):3-12.
3. Karlsson E, Shaat N, Groop L: Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4AMODY) and MODY 3 (HNF1A-MODY)? Diabet Med 2008; 25: 788-791.
4. Cervin C, Axler O, Holmkvist J, Almgren P, Rantala E, Tuomi T, Groop L, Dahlbäck B, Karlsson E: An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med 2010; 267: 316-321.
5. Richter S, Shih DQ, Pearson ER, Wolfrum C, Fajans SS, Hattersley AT, Stoffel M: Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1?: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003; 52: 2989-2995.
6. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004; 53: 250-264.
7. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue K; International Society for Pediatric and Adolescent Diabetes: ISPAD Clinical Practice Consensus Guidelines 2006-2007. The diagnosis and management of monogenic diabetes in children. Pediatr Diabetes 2006; 7: 352-360.
8. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H; Type 1 Diabetes Trial Net Research Group, European C-Peptide Trial Study Group: Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008; 31: 1966-1971.
9. Besser RE: Determination of C-peptide in children: when is it useful? Pediatr Endocrinol Rev 2013; 10: 494-502.
10. Besser RE, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT: Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 2011; 34: 607-609.
11. Besser RE, Shields BM, Casas R, Hattersley AT, Ludvigsson J: Lessons from the mixedmeal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 2013; 36: 195-201.
12. Besser RE, Shields BM, Hammersley SE, Colclough K, McDonald TJ, Gray Z, Heywood JJ, Barrett TG, Hattersley AT: Home urine Cpeptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes. Pediatr Diabetes 2013; 14: 181-188.
13. Besser RE, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Ellard S, Hattersley AT: Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-?/hepatocyte nuclear factor 4-? maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 2011; 34: 286-291.
14. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 34(suppl 1):S62-S69.
15. Y?lmaz Aglad?oglu S, Aycan Z, Çetinkaya S, Ba? VN, Onder A, Peltek Kendirci HN, Ceylaner S: Screening for mutations in Turkish children with a clinical diagnosis of maturity onset diabetes of youth (MODY). Pediatr Diabetes 2013; 14(suppl 18):132.
16. Ludvigsson J, Heding LG, Larsson Y, Leander E: C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control. Acta Paediatr Scand 1977; 66: 177-184.
17. Steck AK, Winter WE: Review on monogenic diabetes. Curr Opin Endocrinol Diabetes Obes 2011; 18: 252-258.
18. Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT: A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 2009; 26: 437-441.
19. Fajans SS, Bell GI, Polonsky KS: Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345: 971-980.
20. Ludvigsson J, Carlsson A, Forsander G, Ivarsson S, Kockum I, Lernmark A, Lindblad B, Marcus C, Samuelsson U: C-peptide in the classification of diabetes in children and adolescents. Pediatr Diabetes 2012; 13: 45-50.
21. Katz LE, Jawad AF, Ganesh J, Abraham M, Murphy K, Lipman TH: Fasting C-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis. Pediatr Diabetes 2007; 8: 53-59.
22. Tung YC, Lee JS, Tsai WY, Hsiao PH: Evaluation of beta cell function in diabetic Taiwanese children using a 6-min glucagon test. Eur J Pediatr 2008; 167: 801-805.
23. Wang L, Lovejoy NF, Faustman DL: Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 2012; 35: 465-470.
24. Urbanová J, Rypá?ková B, Ku?era P, And?l M, Heneberg P: Should the negativity for islet cell autoantibodies be used in a prescreening for genetic testing in maturity-onset diabetes of the young? The case of autoimmunity-associated destruction of pancreatic ?-cells in a family of HNF1A-MODY subjects. Int Arch Allergy Immunol 2013; 161: 279-484.